Small-cap healthcare names delivered a mixed session, with a platform breakthrough at one diagnostics specialist offset by cautious guidance and a boardroom reshuffle elsewhere in the sector. The standout was a commercial milestone rather than a trading update, underscoring how far a single contract win can move sentiment in thinly-traded biotech stocks.
Oxford BioDynamics lands first Orion deal
Oxford BioDynamics (LON:OBD) has signed its first commercial agreement for EpiSwitch Orion, its 3D genomics platform, striking the deal as part of a UK-funded biomarker programme targeting psoriatic arthritis. The agreement marks a shift from research collaboration to paying customer for the platform, a validation point investors have been waiting for. Shares rose 8.333% to 0.13p on the news.
NIOX confirms first-half trading in line as it plans capital return
NIOX GROUP (LON:NIOX) said first-half trading came in as expected, with chief executive Jonathan Emms pointing to a stronger second half driven by the commercial rollout of NIOX PRO and higher pricing taking effect in Japan. Despite the reassurance on guidance, the shares fell 4.02% to 62.0p as the market weighed the back-half-loaded outlook against near-term momentum.
Allergy Therapeutics names Weiner-Trapness chairman
Allergy Therapeutics (LON:AGY) has installed Helge Weiner-Trapness, currently its Chief Strategy Officer, as Executive Chairman, a move that comes as the AIM-listed immunotherapy specialist weighs a dual listing in Hong Kong. The leadership change places a strategy-focused executive at the helm as the company explores expanding its capital markets footprint. Shares slipped 2.778% to 5.25p.
